RxDoctor Payments DataLook up a doctor →

Anthony Altobelli, MD

Cardiovascular Disease · East Brunswick, NJNPI 1003843905

Payments from drug & device makers

$137,343in general payments, 2019–2025

Across 618 payments — averaging $222.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$53K
  • Esperion Therapeutics, Inc.$44K
  • Lilly USA, LLC$17K
  • Johnson & Johnson$11K
  • Novartis$8K
  • Impulse Dynamics (USA) Inc.$1K
  • plus $4K from 31 others

What the payments were for

  • Consulting fees$5000%
  • Speaking & faculty fees$123,72090%
  • Travel & lodging$2,1312%
  • Food & beverage$10,9938%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,343 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$359,251
Medicare patients
1,349
Services billed
3,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban311$395,103
XareltoRivaroxaban135$189,114
EntrestoSacubitril/Valsartan122$187,744
JardianceEmpagliflozin48$67,486
FarxigaDapagliflozin Propanediol27$32,723
MultaqDronedarone Hcl11$25,037
Repatha SureclickEvolocumab30$22,056
NexletolBempedoic Acid18$20,383
BrilintaTicagrelor22$18,954
LivaloPitavastatin Calcium19$12,964
NexlizetBempedoic Acid/Ezetimibe14$12,092
Metoprolol Succinate607$9,138
Atorvastatin Calcium721$8,648
Dabigatran EtexilateDabigatran Etexilate Mesylate23$8,388
Icosapent Ethyl13$8,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$131$395,103311 claims
Johnson & JohnsonXarelto$10,583$189,114135 claims
NovartisEntresto$7,889$187,744122 claims
Boehringer IngelheimJardiance$52,796$67,48648 claims
AstraZenecaFarxiga, Brilinta$260$51,67749 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$44,192$32,47532 claims
Sanofi-aventis U.S. LLCMultaq$12$25,03711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in East Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →